The FDA has authorized Aletta, a robotic device built by Dutch medical technology company Vitestro that independently performs the entire blood draw process under a phlebotomist’s supervision, marking the first authorization of its kind for an autonomous blood collection device. The agency cleared the device through its De Novo pathway, reserved for novel low-to-moderate risk devices, and established a new set of special controls covering labeling, performance testing, and clinical requirements that future similar devices will need to meet. Michelle Tarver, director of the FDA’s Center for Devices and Radiological Health, tied the clearance to a specific staffing problem in U.S. health care: “This authorization reflects the FDA’s commitment to advancing innovative medical devices that help meet a critical public health need while maintaining the safety and effectiveness patients deserve. Blood draws are one of the most commonly performed medical procedures in the United States, yet patients may face delays due to a growing shortage of trained phlebotomists.”
How Aletta Actually Draws Blood
A trained phlebotomist starts and oversees each session, and the FDA says one phlebotomist can supervise up to three of the devices running at the same time. Once a patient positions their arm and the process begins, Aletta uses near-infrared light and Doppler ultrasound to locate a suitable vein and distinguish it from nearby arteries; if it can’t identify an appropriate vein, it stops the procedure rather than proceeding. From there, the device handles the rest of the process on its own: applying a tourniquet, disinfecting the skin, inserting and removing the needle, swapping collection tubes as needed, and applying a bandage when it’s finished.
The Safety Checks Built Into the Process
The system includes several built-in safeguards described in the FDA’s authorization: it applies disinfectant continuously throughout the vein-scanning process, automatically detaches the needle if a patient moves too much during the draw, and relies on sensors designed to detect unsafe conditions and alert the supervising phlebotomist. Those controls appear to be central to how the FDA evaluated a device that, unlike most blood-draw technology, is meant to work without a human directly performing the needle stick.
What the Clinical Data Actually Showed
The FDA’s announcement describes Aletta’s clinical performance only in general terms, stating that its blood draw success rates were comparable to or better than trained phlebotomists across a broad range of patients, including those with varying health statuses, self-reported difficult vein access, and different skin tones, and that device-related adverse events were uncommon and mild. The agency didn’t publish specific sample sizes, exact success-rate percentages, or adverse event counts in this release, and independent trade coverage from Patient Care Online confirms that gap directly, noting the FDA’s announcement “did not provide the study size, numerical success rates, comparator methods, confidence intervals, specific adverse-event types, or peer-reviewed trial citation.” So these results should be read as a qualitative summary of the clinical evidence rather than a fully quantified data set.
A Dutch Startup Now Positioned for the U.S. Market
Vitestro, headquartered in Utrecht, Netherlands, was founded in 2017 by Toon Overbeeke and Brian Joseph after each separately experienced frustrating blood draws, one involving a friend’s father going through chemotherapy, the other involving a young child’s recurring blood tests, and has grown to roughly 100 employees since. Aletta received CE mark approval for use in Europe in August 2024, and the company raised a $70 million Series B round earlier this year, backed in part by Labcorp Venture Fund, Mayo Clinic, and Sutter Health, specifically to fund its FDA regulatory pathway and prepare for U.S. commercial readiness. With that authorization now in hand, Vitestro’s stated plan is to expand from its European base into U.S. clinical and commercial settings next.
